Arimidex is indicated for the: • Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. • Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women. Easy-to-read patient leaflet for Arimidex. Includes indications, proper use, special instructions, precautions, and possible side effects. Anastrozole is a non-steroidal aromatase inhibitor used to treat breast cancer in postmenopausal women. Learn about side effects, drug interactions, dosages, warnings, and more. ARIMIDEX® (anastrozole) Tablets for Oral Administration. DESCRIPTION. ARIMIDEX (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. I have always had some bone pain from the arimidex and one of the side effects was hot flashes (but I started right after my ovaries were removed so who knows which was the cause) and hair loss. If you are postmenopausal and have been diagnosed with hormone receptor-positive early breast cancer, and have recently undergone surgery with radiation, and/or chemotherapy, ARIMIDEX may be right for you. Evista (raloxifene) a drug prescribed for the prevention and treatment of osteoporosis. Side effects may include bronchitis, vomiting, insomnia, breast pain, and sore throat. Dosage, and drug interactions, pregnancy, and breastfeeding information are provided. User Reviews for Arimidex. The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care. This is reproduced from Boren et al. 2011 who did an excellent study and also compared their results with earlier work. Their top 3 exercises for Glute Medius were side plank abduction with dominant leg down, side plank abduction with dominant leg up and single leg squat (in that order). ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.